Here's a classic biotech puzzle: a company announces that its drug successfully hit the main goal in a big, important Phase 3 trial. The stock should go up, right? Not always. Shares of Viridian Therapeutics Inc. (VRDN) were down a brutal 38% in Monday's premarket trading, even after the company reported positive topline results from its REVEAL-1 Phase 3 trial for elegrobart, a treatment for thyroid eye disease (TED).

So what gives? The data, on its face, looks good. The trial met its primary endpoint. For the main problem TED causes—proptosis, which is when the eyes bulge forward—elegrobart showed a responder rate of 54% for patients dosed every four weeks and 63% for those dosed every eight weeks. That's compared to just 18% for the placebo group at week 24. It also helped with double vision, with 51% of patients on the four-week regimen seeing complete resolution versus 16% on placebo. The drug was reportedly well-tolerated too, with low rates of hearing issues.

This is where the market's harsh math comes in. It's not just about beating a placebo; it's about beating expectations and, more importantly, beating the competition. According to analysts, the numbers that really matter—the placebo-adjusted rates—came in softer than hoped. William Blair pointed out that the placebo-adjusted proptosis responder rates were 36% for the four-week dose and 45% for the eight-week dose. Investors, it seems, were looking for something in the 51% to 73% range.

That gap is likely what's spooking people. A Jefferies analyst, cited in reports, said the data does lower the risk for Viridian by giving it two shots on goal in the TED space. But the concern is that elegrobart's "weaker efficacy versus peers could trigger investor concerns around commercial viability." In other words, in a market with existing treatments, being just okay might not be enough to win a big slice of the pie.

Not everyone thinks the sky is falling. William Blair added that the stock drop looks like an "overreaction" and that the share price should recover somewhat as investors have more time to dig into the full data set. Analyst Lachlan Hanbury-Brown also noted there are several factors that could explain the weaker placebo-adjusted change.

Looking beyond today's drama, Viridian's story isn't over. The company has a second pivotal Phase 3 trial for elegrobart in chronic TED, called REVEAL-2, on track to report results in the second quarter of 2026. It plans to submit its application to the FDA in early 2027. Financially, the company is in a solid position, ending its last fiscal year with $875 million in cash. It believes that war chest will fund its operations all the way to profitability, banking on future revenue from both elegrobart and another drug, veligrotug, which is under Priority Review at the FDA with a decision date set for June 30.

The competitive landscape adds another layer. Just a few months ago, in December 2025, Argenx SE (ARGX) decided to stop its own Phase 3 trials for a TED treatment. That news was initially seen as a clear positive for Viridian, removing a potential rival. But today's reaction suggests that even with one competitor stepping aside, the bar for success in the eyes of investors remains very high.

So, Viridian's stock is caught in a tug-of-war between solid trial results and the market's higher expectations. The company cleared the scientific hurdle, but now it faces the equally tough challenge of convincing investors that its drug has a winning commercial future.